SCHEMBL4248367

SCHEMBL4248367

Cc1cccc(O)c1-c1cccnc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 0.51
CYP3A4 P08684 5/20 0.49
CYP2D6 P10635 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2B6 P20813 3/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2E1 P05181 2/20 0.49
CYP1A2 P05177 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HSD17B1 P14061 1/20 0.48
HSD17B2 P37059 1/20 0.48
MKNK1 Q9BUB5 3/20 0.45
MKNK2 Q9HBH9 3/20 0.45
ACLY P53396 2/20 0.45
MEN1 O00255 1/20 0.44
PSIP1 O75475 1/20 0.44
AXL P30530 1/20 0.44
KDM4E B2RXH2 3/20 0.43
HTT P42858 3/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21476509 0.87 CYP2A6 (0.60) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL2936656 0.82 MKNK1 (0.49) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
Pyridine SCHEMBL28912289 0.82 TRPA1 (0.41) CYP2A6ALDH1A1HSD17B1HSD17B2HSD17B10
SCHEMBL18528875 0.81 CYP2A6 (0.52) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
Hydrochloric Acid SCHEMBL2939932 0.81 MKNK1 (0.47) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL27750360 0.80 MKNK1 (0.47) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL12117598 0.80 CYP2A6 (0.54) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL6172101 0.80 CYP2A6 (0.53) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL21742627 0.77 CYP2A6 (0.51) CYP2A6CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL6237449 0.77 MKNK1 (0.62) CYP2A6CYP3A4CYP2C19CYP1A2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279237-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-08-22 US claimed
EP-4419532-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-08-28 EP disclosed
WO-2023066825-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-27 WO disclosed
EP-3325471-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS Genzyme Corporation (US) 2018-05-30 EP disclosed
WO-2017015267-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS GENZYME CORPORATION (US) 2017-01-26 WO disclosed
EP-2081931-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen Inc. (US) 2009-07-29 EP disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279237-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 CYP2A6 2336/4885CYP3A4 1311/4885CYP2D6 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.